Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    Home»Metals»Annual Report on Form 20-F for Fiscal Year 2019 of Aluminum Corporation of China Limited Now Available
    Metals

    Annual Report on Form 20-F for Fiscal Year 2019 of Aluminum Corporation of China Limited Now Available

    Marie JonesBy Marie JonesApril 23, 2020Updated:April 24, 2020No Comments1 Min Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Aluminum Corporation of China Limited (the “Company”; NYSE “ACH”; SEHK “2600”; SSE “601600”) announces that the Company’s annual report for the 2019 fiscal year filed with the SEC on April 22, 2020 can be accessed via the following link:

    http://www.chalco.com.cn/chalcoen/tzzgx/pr/webinfo/2020/04/1587581225293050.htm.

    A paper copy of the Company’s complete annual report will be provided to any shareholder without charge upon written request to Aluminum Corporation of China Limited at No. 62 North Xizhimen Street, Haidian District, Beijing, PRC 100082.

    Background information:

    Aluminum Corporation of China Limited is a leading enterprise in non-ferrous metal industry in China. The scope of business of the Company primarily includes bauxite and coal mining, alumina refining, primary aluminum smelting, trading of alumina, primary aluminum, other non-ferrous metal products, coal products and raw and ancillary materials in bulk and power generation. The Company was established as a joint stock limited company incorporated in the People’s Republic of China. The Company’s American Depository Shares and H Shares are listed on the New York Stock Exchange, Inc. and the Stock Exchange of Hong Kong Limited respectively. The Company’s A Shares are listed on the Shanghai Stock Exchange.

    For further queries, please visit http://www.chalco.com.cn

    Aluminum Corporation
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleCStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the first-in-class precision therapy avapritinib in two gastrointestinal stromal tumor indications
    Next Article Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market

    Related Posts

    GMG Appoints Nine-Time Motocross World Champion Antonio Cairoli as Brand Ambassador and Invites Visitors to EICMA 2026

    October 19, 2026

    Casa Minerals Announces Closing of Second Tranche of Private Placement

    October 16, 2026

    Focus Graphite Advances Lac Knife Toward Construction Readiness with Up to C$1.93 Million in Combined Government Infrastructure Support

    October 15, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • The 16th Asian Logistics, Maritime and Aviation Conference takes place on 16 and 17 November
    • DataTracks Extends Pillar Two Filing Support to Australia and New Zealand
    • Formerra Adjusts Transportation Surcharge Amid Continued Freight and Logistics Pressures
    • CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth
    • Twin lighting fairs open with some 3,000 exhibitors showcasing global lighting solutions
    • 18th Hong Kong International Wine & Spirits Fair opens next week
    • Quant Group Validates Its Physical AI Foundation Model in a Working Restaurant Kitchen
    • Australian Made puts Singaporean approval centre-stage of its new campaign launch
    • Micot Pharma Showcases First-in-Class, Brain-Penetrant TrkB Agonist MT200605 at World Stroke Congress, Building the Case for Global Partnerships and Commercialization
    • Quant Group (02685.HK) Enters into Framework Procurement Agreement for Up to 2,000 Embodied-AI Robots Solutions – Physical AI Business Poised for Re-rating
    © 2026 BusinessNewsAsia.com

    Type above and press Enter to search. Press Esc to cancel.